All articles tagged with #heart failure
UMCG-led studies suggest adding a low-dose digoxin to standard heart failure therapy reduces cardiovascular death risk and HF-related hospitalizations. A broader meta-analysis found a significant ~25% reduction in HF admissions, supporting digoxin’s safety and cost-effectiveness at under ten cents per day. If confirmed, these findings could influence guidelines and broaden access to this inexpensive, centuries-old treatment.
Casey Gould faced a life-threatening heart condition discovered during labor when her ejection fraction fell to 13%, prompting an emergency C-section and a days-long ICU coma. Doctors placed an Impella heart pump to support her circulation, and she gradually recovered. Her EF normalized, but future pregnancies remain high-risk and require close monitoring; today she is healthy with her one-year-old son.
SPIRIT-HF found no meaningful reduction in the primary endpoint (HF hospitalizations or cardiovascular death at 24 months) with spironolactone in patients with HFpEF or HFmrEF. The spironolactone group had more total hospitalizations and adverse events (hypotension, renal issues, hyperkalemia). A high COVID-19–related discontinuation and limited power may have muted efficacy signals; a meta-analysis with TOPCAT also showed no significant benefit, though ongoing registries may clarify safety and efficacy.
A ten-year study of about 25,000 low-income Black and White adults in the southeastern US found that higher daily sodium intake increases heart‑failure risk; each extra 1,000 mg of sodium per day raises risk by ~8%, and participants averaging 4,200 mg/day had a 27% incidence of heart failure. Following guidelines of 2,300 mg/day (1,500 mg for hypertension) and reducing intake toward 4,000 mg/day could prevent ~6.6% of new heart‑failure cases over a decade, though the study relied on self-reported data and may not generalize to all populations.
A Vanderbilt-led study of 25,306 adults found that consuming about 4,200 mg of sodium daily—almost twice the recommended limit—was linked to a 15% higher risk of developing heart failure, with each additional 1,000 mg raising risk by 8% independent of other factors. Even modest reductions in average sodium could prevent a meaningful portion of new heart failure cases over 10 years (about 6.6% in the studied population), but most sodium comes from packaged foods, presenting challenges for lowering intake, especially in high-risk, low-resource communities; multilevel public health efforts will be needed.
A Jackson Heart Study analysis found that waist circumference and waist-to-height ratio—measures of central obesity—predicted future heart failure risk, while BMI did not; higher systemic inflammation (hs-CRP) partially mediated this link (about 25–29%), suggesting fat distribution and inflammation drive risk; the study's limitations include a single-site African-American cohort and pending peer review; implications point to prioritizing central obesity and inflammation management through lifestyle changes to reduce heart failure risk.
A study presented at the AHA Lifestyle Scientific Sessions 2026 finds abdominal/visceral fat predicts future heart failure more accurately than BMI, with higher belly fat linked to greater risk even in people with a normal BMI; inflammation may account for about one-third of this connection.
Japan’s health ministry conditionally approved two therapies derived from reprogrammed iPS cells—ReHeart for severe heart failure and Amusepri for Parkinson’s—marking the first medical treatments of this kind and signaling a new era in regenerative medicine, though extended safety and efficacy data from more patients are still needed.
Japan granted conditional approval for two world-first stem cell therapies—AMCHEPRY for Parkinson's and RiHEART for severe heart failure—using induced pluripotent stem cells to replace or repair damaged tissue, with ongoing data collection and long-term safety monitoring.
Japan grants conditional, time-limited approvals for Amchepry (Parkinson’s) and ReHeart (heart failure), two iPS-cell therapies that could reach patients within months and mark the first commercially available iPS-based medical products, based on small trials showing safety and some symptom improvements with ongoing monitoring.
Ray J’s Shreveport performance featured a moment that appeared to show blood streaming from his eyes and a visible chest device, as he has said doctors told him his heart is failing with only months to live. Some observers believe the blood was a theatrical effect, while others note his health claims and eight prescribed medications. Doctors reportedly advised bed rest and avoiding alcohol, and Ray J has suggested he might need a pacemaker or defibrillator as heart damage from heavy substance use is cited.
A Florida construction project manager in his early 30s blamed fatigue and weight gain on aging and new fatherhood, but after his symptoms worsened he was diagnosed with left ventricular non-compaction cardiomyopathy (LVNC) and a genetic muscle disorder, leading to advanced heart failure. He underwent a left ventricular assist device (LVAD) implantation to sustain circulation while awaiting a heart transplant, highlighting a rising trend of heart failure in younger adults driven by obesity, diabetes, and high blood pressure.
Chuck Negron, founding lead singer of Three Dog Night behind hits like 'Joy to the World' and 'One,' died at 83 in Studio City from complications of heart failure and COPD; once plagued by drug issues, he sobered in 1991 and later reconciled with bandmates. He is survived by his wife Ami Albea Negron and five children, including Berry Oakley Jr.
A JACC study shows progress against U.S. heart disease has stalled as obesity and diabetes rise; the five deadliest conditions—coronary heart disease, heart attack, heart failure, peripheral artery disease, and stroke—continue to cause the most deaths and disability, driven by preventable risk factors such as hypertension, obesity, diabetes, high LDL cholesterol, and smoking.
A study by the University of Sydney reveals that type 2 diabetes causes specific molecular and structural changes in the human heart, including fibrosis and altered energy production, which contribute to a higher risk of heart failure, offering new insights for treatment and diagnosis.